Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

XSEC:300357 Stock Report

Market Cap: CN¥10.4b

Zhejiang Wolwo Bio-Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Zhejiang Wolwo Bio-Pharmaceutical has been growing earnings at an average annual rate of 1.7%, while the Pharmaceuticals industry saw earnings growing at 6.1% annually. Revenues have been growing at an average rate of 8% per year. Zhejiang Wolwo Bio-Pharmaceutical's return on equity is 11.9%, and it has net margins of 33.6%.

Key information

1.65%

Earnings growth rate

1.65%

EPS growth rate

Pharmaceuticals Industry Growth10.90%
Revenue growth rate8.03%
Return on equity11.93%
Net Margin33.59%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Wolwo Bio-Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300357 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25938315446119
31 Dec 24925318436120
30 Sep 24905312427122
30 Jun 24891311410122
31 Mar 24881317401118
31 Dec 23848310384112
30 Sep 23870292380108
30 Jun 23893316379107
31 Mar 23882328365104
01 Jan 23896349361106
30 Sep 22888391357103
30 Jun 22849372339100
31 Mar 2284135934195
31 Dec 2180833833688
30 Sep 2176532432078
30 Jun 2172431930375
31 Mar 2169130828370
31 Dec 2063627826361
30 Sep 2063028125756
30 Jun 2062427525748
31 Mar 2061227425742
31 Dec 1963929825937
30 Sep 1961529025629
30 Jun 1955625923519
31 Mar 1953224722216
31 Dec 1850123320512
30 Sep 1847822718810
30 Jun 1843921117111
31 Mar 184112001639
31 Dec 173861861586
30 Sep 173671751565
30 Jun 173441541570
31 Mar 173241391530
31 Dec 163121291510
30 Sep 163031291410
30 Jun 162831211360
31 Mar 162771221300
31 Dec 152671181260
30 Sep 152611161210
30 Jun 152521121180
31 Mar 152471101160
31 Dec 142401001220
30 Sep 14228901210
30 Jun 14211781160

Quality Earnings: 300357 has high quality earnings.

Growing Profit Margin: 300357's current net profit margins (33.6%) are lower than last year (36%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300357's earnings have grown by 1.7% per year over the past 5 years.

Accelerating Growth: 300357's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300357 had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.2%).

Return on Equity

High ROE: 300357's Return on Equity (11.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 03:47
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.
Yaming LiuFounder Securities Co., Ltd.